Saniona AB (publ) (STO:SANION)

Sweden · Delayed Price · Currency is SEK

18.62

-0.96 (-4.90%)

At close: Feb 27, 2026

131.30% (1Y)

Market Cap	2.57B
Revenue (ttm)	434.40M
Net Income (ttm)	284.67M
Shares Out	138.03M
EPS (ttm)	2.15
PE Ratio	8.66
Forward PE	30.71
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,843,857
Average Volume	775,053
Open	19.58
Previous Close	19.58
Day's Range	18.38 - 20.45
52-Week Range	5.41 - 28.30
Beta	1.39
RSI	28.07
Earnings Date	Feb 26, 2026

About Saniona AB

Saniona AB (publ), a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of treatments for rare disease patients in Sweden, the United States, Germany, Denmark, and the United Kingdom. It also develops medicines modulating ion channels. The company’s product includes Tesofensine, a monoamine reuptake inhibitor that has completed Phase 3 clinical trial to treat people with obesity; and Tesomet, an oral investigational therapy, which is in Phase 2b clinical trial for the treatment of hypothalamic ... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 2011

Employees 31

Stock Exchange Nasdaq Stockholm

Ticker Symbol SANION

Full Company Profile

Financial Performance

In 2025, Saniona AB's revenue was 434.40 million, an increase of 29.80% compared to the previous year's 334.67 million. Earnings were 284.67 million, an increase of 50.85%.

Financial Statements

News

Saniona AB (FRA:30S) Q3 2025 Earnings Call Highlights: Strategic Partnerships and Financial ...

Saniona AB (FRA:30S) Q3 2025 Earnings Call Highlights: Strategic Partnerships and Financial Strength Propel Growth

3 months ago - GuruFocus

Q3 2025 Saniona AB Earnings Call Transcript

3 months ago - GuruFocus